At the May 2018 Managing IP PTAB Forum in New York, Corinne Atton presented statistics relating to the fate of compound/composition of matter claim challenges in IPRs filed against patents that have been identified as reading on CDER-listed biologic drugs, versus IPRs filed against Orange Book listed patents.
Of note, as of March 31, 2018:
- The institution rate of compound/composition claim challenges in the Orange Book context and in the Biologic drug context is approximately the same: 74% (Orange Book) to 73% (Biologic drug);
- In final written decisions, in the Orange Book patent context, compound claims have been found unpatentable in only 1 IPR.
Biologic Drug IPR Petitions include IPR petitions relating to CDER-listed biologic products and drugs for which follow-on products are approved under the 505(b)(2) pathway, such as insulin. IPR petitions relating to manufacturing patents that may be relevant to multiple products (for example, U.S. Patent No. 6,331,415 (a “Cabilly” patent)) are not included.
Orange Book Drug IPR Petitions include IPR petitions relating to patents that have been listed in the FDA’s Orange Book.
BiologicsHQ and materials published on BiologicsHQ are published for informational purposes only. Neither the information nor any opinion expressed on BiologicsHQ constitute legal advice, create an attorney-client relationship, or constitute a solicitation for business.